INDP Indaptus Therapeutics Inc
Company Analysis
Latest News
Indaptus Raises $24 Million as Its Stock Doubles in a Week — But Can a Cash-Burning Biotech With a Paused Drug Trial Justify the Momentum?
Shares of Indaptus Therapeutics (INDP) surged +15.9% to $2.41 on September 10, capping a week in which the stock roughly doubled from $1.17, after the company...
🟢 Indaptus Therapeutics is trading 15.87% up today after announcing a $24 million private placement
Indaptus Therapeutics is trading at $2.41, up 15.87% after announcing a $24 million private placement. - The financing includes 20,338,974 common shares and...
Indaptus Therapeutics Announces $24 Million Private Placement of Common Stock
Indaptus Therapeutics, Inc. entered into a stock purchase agreement on September 8, 2026, to sell 20,338,974 shares of its common stock in a private placement,...
🔴 Indaptus Therapeutics is trading 6.15% down in pre-market with no confirmed company-specific catalyst
Indaptus Therapeutics is trading 6.15% down at $1.95 after no confirmed company-specific catalyst was identified for September 10, 2026. - Available coverage...
🟢 Indaptus Therapeutics is trading 16.71% up today — No confirmed company-specific catalyst identified
Indaptus Therapeutics is trading 16.71% up now at $2.16, with no confirmed company-specific catalyst identified for the September 9 move. - It rose 51.64% to...
🔴 Indaptus Therapeutics is trading 5.4% down in pre-market with no confirmed catalyst
Indaptus Therapeutics is trading at $1.75, down 5.41%, with no confirmed company-specific catalyst identified for the September 9 pre-market decline. • Closed...
🔴 Indaptus Therapeutics is trading 6.45% down in after-hours trading with no confirmed company-specific catalyst
Indaptus Therapeutics is trading 6.45% down in after-hours trading at $1.73, with no confirmed company-specific announcement or late-breaking catalyst...
🟢 Indaptus Therapeutics is trading 11.48% up today with no confirmed company-specific catalyst
Indaptus Therapeutics is trading 11.48% up at $1.36, after rising from the September 4 close of $1.22, with no confirmed company-specific catalyst identified...
🟢 Indaptus Therapeutics is trading 5.74% up today with no confirmed company-specific catalyst
Indaptus Therapeutics is trading 5.74% up at $1.29, with no confirmed company-specific catalyst identified for the September 8, 2026 move. - The stock rose...
🟢 Indaptus Therapeutics is trading 10.02% up today in pre-market with no confirmed catalyst identified
Indaptus Therapeutics is trading 10.02% up now at $1.34, with no confirmed company-specific announcement explaining the September 8 pre-market move, following...
🟢 Indaptus Therapeutics is trading 6.6% up in pre-market with no confirmed catalyst identified
Indaptus Therapeutics is trading 6.56% up at $1.30 in pre-market, with no clear company-specific catalyst identified. - Searches found no clear...
🔴 Indaptus Therapeutics is trading 13.93% down in after-hours trading — no clear catalyst identified
Indaptus Therapeutics is trading 13.93% down at $1.05 after closing at $1.22 on September 4, 2026, with no clear catalyst identified for the after-hours...
🟢 Indaptus Therapeutics is trading 5.17% up today — no fresh company-specific announcement identified
Indaptus Therapeutics is trading up +5.17% at $1.22 on September 4, 2026, with no fresh company-specific announcement identified to explain the move. - Latest...
🟢 Indaptus Therapeutics is trading 6.19% up today after announcing amended $100 million at-the-market offering
On September 2, 2026, Indaptus Therapeutics is trading at $1.20, up +6.19%, after announcing an amended and restated at-the-market offering allowing up to $100...
🟢 Indaptus Therapeutics is trading 6% up in after-hours trading after launching amended $100 million equity offering
Indaptus Therapeutics is trading at $1.20, up 6.19% in after-hours trading after launching an amended $100 million at-the-market equity offering through H.C....
Indaptus Therapeutics Launches $100M Offering, Addressing Going Concern Risks
Indaptus Therapeutics established an at-the-market (ATM) equity program to sell up to $100 million of common stock. H.C. Wainwright & Co. will manage the sales...
🔴 Indaptus Therapeutics is trading 5.17% down today as XBI falls 2.31%
Indaptus Therapeutics is trading 5.17% down now at $1.10 amid weakness across biotechnology stocks. - XBI, the sector ETF, is down 2.31% during regular...
🟢 Indaptus Therapeutics is trading 7% up today amid broader market gains
Indaptus Therapeutics is trading 7.02% up now at $1.22, supported by the Nasdaq rising 1.34% and S&P 500 gaining 0.59%. - No new company-specific announcement...
🔴 Indaptus Therapeutics is trading 5.18% down today amid a 58,895,000-share resale registration
Indaptus Therapeutics is trading 5.18% down at $1.10 amid continued volatility and supply concerns following its August 20, 2026 surge. - An August 17 SEC...
🟢 Indaptus Therapeutics is trading 8% up in pre-market amid Nasdaq futures rising 0.85%
Indaptus Therapeutics is trading 7.97% up at $1.25, possibly reflecting firmer pre-market sentiment as Nasdaq futures rise 0.85%. - A volatile stretch...